flutamide has been researched along with Hormone-Dependent Neoplasms in 60 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiandrogen flutamide has been reported to exert antiproliferative actions on breast cancer both in vitro and in vivo." | 7.69 | Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells. ( Boccuzzi, G; Brignardello, E; Di Monaco, M; Gatto, V; Leonardi, L, 1995) |
| " A large randomized study comparing the non-steroidal antiandrogen, bicalutamide, with flutamide, each in combination with luteinizing hormone-releasing hormone (LHRH) analogs, showed that after a median follow-up of 49 weeks, the time to treatment failure was significantly longer for the bicalutamide patients compared with the flutamide patients (p = 0." | 3.78 | Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. ( Blackledge, G; Kolvenbag, G; Nash, A, 1996) |
| "The antiandrogen flutamide has been reported to exert antiproliferative actions on breast cancer both in vitro and in vivo." | 3.69 | Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells. ( Boccuzzi, G; Brignardello, E; Di Monaco, M; Gatto, V; Leonardi, L, 1995) |
| "Men with prostate cancer who lacked radiographically detectable metastases were treated in a prospective trial of IAD." | 2.77 | Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. ( Chen, S; Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Jiang, PY; Kuo, KF; Pitzel, P; Yu, EY, 2012) |
| "Although prostate cancer-specific survival was not statistically significantly different between treatment arms at 5 years (P = ." | 2.74 | Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. ( Bae, K; Hanks, GE; Hussain, MH; Ray, ME; Sandler, HM; Shipley, WU, 2009) |
| "To study whether use of neoadjuvant androgen deprivation therapy (N-ADT) combined with whole pelvic radiotherapy (WPRT) for high-risk prostate cancer patients was associated with survival benefit over prostate radiotherapy (PORT) only." | 2.74 | Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. ( Antczak, A; Baczyk, M; Kwias, Z; Martenka, P; Milecki, P; Skowronek, J, 2009) |
| "In the past 20 years, 3,500 prostate cancer patients have been recruited in 16 phase III trials in untreated and advanced disease and in seven phase II trials in hormone-refractory, metastatic disease." | 2.69 | European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996. ( Denis, L, 1998) |
| " In order to investigate the optimal way to eliminate tumor flare, we have treated patients with one of three different antiandrogen regimens used in combination with gonadotrophin-releasing hormone (GnRH) agonist." | 2.66 | The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. ( Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G, 1988) |
| "Flutamide monotherapy is an alternative for some patients." | 2.49 | First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease. ( , 2013) |
| "The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part." | 2.49 | [Hormonal treatment in prostate cancer]. ( Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F, 2013) |
| "For the endocrine therapy of prostate cancer, chlormadinone acetate, flutamide and bicalutamide are or will be available in Japan." | 2.40 | [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications]. ( Akakura, K; Furuya, Y; Ito, H, 1998) |
| "Flutamide is an approved anti-androgen that has been incorporated in many of the combined androgen blockade studies." | 2.40 | Anti-androgens and other hormonal therapies for prostate cancer. ( Richie, JP, 1999) |
| "Suramin has been reintroduced in trials of chemohormonal intervention." | 2.39 | [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. ( Crawford, ED; DeAntoni, E, 1995) |
| " Pharmacokinetic study with compound 10 at an oral dose of 10." | 1.37 | Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. ( Dalela, D; Gupta, G; Jain, A; Kumar, L; Kumar, R; Lal, J; Lal, N; Maikhuri, JP; Pandey, SK; Prabhakar, YS; Sarswat, A; Sharma, S; Sharma, VL; Verma, V, 2011) |
| "Flutamide pre-treatment completely prevented this increase." | 1.35 | Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. ( Farmer, PB; Gescher, AJ; Greaves, P; Mellon, JK; Pathak, S; Sharma, RA; Singh, R; Steward, WP; Verschoyle, RD, 2008) |
| "We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis." | 1.34 | [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. ( Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S, 2007) |
| "The androgen dependent prostate cancer cell line LNCaP was cultured in RPMI 1640 medium and treated with different concentrations of DHT(2, 10, 50 nmol/L) and flutamide (100 nmol/L)." | 1.33 | [Effect of dihydrotestosterone on the transcriptions and expressions of Smad3 and Smad4 in LNCaP cell line]. ( Gu, RG; Ma, QZ; Zhou, CW, 2006) |
| "Flutamide is a nonsteroidal antiandrogen that is frequently used for total androgen blockage in the treatment of advanced prostate cancer." | 1.32 | Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells. ( Bolaños, O; Carmena, MJ; Montalvo, L; Prieto, JC; Rodríguez-Henche, N; Sánchez-Chapado, M, 2004) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen-independence is frequently observed later." | 1.31 | Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. ( Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T, 2002) |
| "Patients with progressive prostate cancer were treated with bicalutamide 200 mg daily." | 1.30 | Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. ( Brett, C; Kelly, WK; Kolvenbag, G; Liebertz, C; Mazumdar, M; Scher, HI; Schwartz, L; Schwartz, M; Shapiro, L, 1997) |
| "in 1941, hormonal treatment of advanced prostatic cancer has been directed primarily at neutralizing testicular androgens by orchiectomy or estrogen therapy." | 1.27 | [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer]. ( Bélanger, A; Dupont, A; Labrie, F; Lacourcière, Y; Monfette, G; Monfette, JE, 1986) |
| "Patients (154) with clinical stage D2 prostate cancer with no previous endocrine therapy or chemotherapy received the combination therapy with the pure antiandrogen Flutamide and the LHRH agonist [D-Trp6]LHRH ethylamide for an average of 22 months (3-49 months)." | 1.27 | Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. ( Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lachance, R; Lacourciere, Y; Monfette, G, 1987) |
| "Flutamide was administered SC at a daily dose of 25 mg/kg." | 1.27 | Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model. ( Redding, TW; Schally, AV, 1985) |
| "An androgen-responsive prostate cancer cell line in monolayer culture provides a means to study the biochemical mechanisms mediating hormonal stimulation of cell proliferation." | 1.27 | Androgen dependence of the Dunning R3327G cell line in monolayer culture. ( Mauvais-Jarvis, P; Mowszowicz, I; Portois, MC; Santen, RJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (15.00) | 18.7374 |
| 1990's | 17 (28.33) | 18.2507 |
| 2000's | 23 (38.33) | 29.6817 |
| 2010's | 11 (18.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goto, T | 2 |
| Ohta, K | 1 |
| Fujii, S | 1 |
| Ohta, S | 1 |
| Endo, Y | 1 |
| Sarswat, A | 1 |
| Kumar, R | 1 |
| Kumar, L | 1 |
| Lal, N | 1 |
| Sharma, S | 1 |
| Prabhakar, YS | 1 |
| Pandey, SK | 1 |
| Lal, J | 1 |
| Verma, V | 1 |
| Jain, A | 1 |
| Maikhuri, JP | 1 |
| Dalela, D | 1 |
| Gupta, G | 1 |
| Sharma, VL | 1 |
| Bastide, C | 1 |
| Bruyère, F | 1 |
| Karsenty, G | 1 |
| Guy, L | 1 |
| Rozet, F | 1 |
| Liu, JB | 1 |
| Dai, CM | 1 |
| Su, XY | 1 |
| Cao, L | 1 |
| Qin, R | 1 |
| Kong, QB | 1 |
| Ray, ME | 1 |
| Bae, K | 1 |
| Hussain, MH | 1 |
| Hanks, GE | 1 |
| Shipley, WU | 1 |
| Sandler, HM | 1 |
| Milecki, P | 1 |
| Baczyk, M | 1 |
| Skowronek, J | 1 |
| Antczak, A | 1 |
| Kwias, Z | 1 |
| Martenka, P | 1 |
| Kawabata, R | 1 |
| Oie, S | 1 |
| Oka, T | 1 |
| Takahashi, M | 1 |
| Kanayama, H | 1 |
| Itoh, K | 1 |
| Tong, da Y | 2 |
| Wen, XQ | 1 |
| Jin, Y | 2 |
| Liu, ZW | 2 |
| Sun, HY | 2 |
| Zhou, FJ | 2 |
| Wu, XY | 2 |
| Takada, T | 1 |
| Ishizuya, Y | 1 |
| Okada, T | 1 |
| Ueda, T | 1 |
| Inoue, H | 1 |
| Hara, T | 1 |
| Yu, EY | 1 |
| Kuo, KF | 1 |
| Gulati, R | 1 |
| Chen, S | 1 |
| Gambol, TE | 1 |
| Hall, SP | 1 |
| Jiang, PY | 1 |
| Pitzel, P | 1 |
| Higano, CS | 1 |
| Lee, YF | 1 |
| Lin, WJ | 1 |
| Huang, J | 1 |
| Messing, EM | 1 |
| Chan, FL | 1 |
| Wilding, G | 2 |
| Chang, C | 1 |
| Zhang, Y | 1 |
| Chen, W | 1 |
| Hu, XK | 1 |
| Gui, ZN | 1 |
| Preston, DM | 1 |
| Torréns, JI | 1 |
| Harding, P | 1 |
| Howard, RS | 1 |
| Duncan, WE | 1 |
| McLeod, DG | 2 |
| Sciarra, A | 1 |
| Monti, S | 1 |
| Gentile, V | 1 |
| Mariotti, G | 1 |
| Cardi, A | 1 |
| Voria, G | 1 |
| Lucera, R | 1 |
| Di Silverio, F | 1 |
| Oh, WK | 1 |
| Manola, J | 1 |
| Bittmann, L | 1 |
| Brufsky, A | 1 |
| Kaplan, ID | 1 |
| Smith, MR | 1 |
| Kaufman, DS | 1 |
| Kantoff, PW | 1 |
| Chen, F | 1 |
| Langenstroer, P | 1 |
| Zhang, G | 1 |
| Iwamoto, Y | 1 |
| See, W | 1 |
| Nabi, G | 1 |
| Seth, A | 1 |
| Dinda, AK | 1 |
| Gupta, NP | 1 |
| de Leval, J | 1 |
| Boca, P | 1 |
| Yousef, E | 1 |
| Nicolas, H | 1 |
| Jeukenne, M | 1 |
| Seidel, L | 1 |
| Bouffioux, C | 1 |
| Coppens, L | 1 |
| Bonnet, P | 1 |
| Andrianne, R | 1 |
| Wlatregny, D | 1 |
| Sato, N | 1 |
| Akakura, K | 2 |
| Isaka, S | 1 |
| Nakatsu, H | 1 |
| Tanaka, M | 1 |
| Ito, H | 2 |
| Masai, M | 1 |
| Montalvo, L | 1 |
| Carmena, MJ | 1 |
| Bolaños, O | 1 |
| Rodríguez-Henche, N | 1 |
| Sánchez-Chapado, M | 1 |
| Prieto, JC | 1 |
| Gu, RG | 1 |
| Zhou, CW | 1 |
| Ma, QZ | 1 |
| Labrie, F | 3 |
| Mercader, M | 2 |
| Sengupta, S | 1 |
| Bodner, BK | 2 |
| Manecke, RG | 2 |
| Cosar, EF | 1 |
| Moser, MT | 2 |
| Ballman, KV | 1 |
| Wojcik, EM | 2 |
| Kwon, ED | 2 |
| Urushibara, M | 1 |
| Ishioka, J | 1 |
| Hyochi, N | 1 |
| Kihara, K | 1 |
| Hara, S | 1 |
| Singh, P | 1 |
| Isaacs, JT | 1 |
| Kageyama, Y | 1 |
| Roca Edreira, A | 1 |
| Aguilera Tubet, C | 1 |
| Villanueva Peña, A | 1 |
| Ballestero Diego, R | 1 |
| Zubillaga Guerrero, S | 1 |
| Pathak, S | 1 |
| Singh, R | 1 |
| Verschoyle, RD | 1 |
| Greaves, P | 1 |
| Farmer, PB | 1 |
| Steward, WP | 1 |
| Mellon, JK | 1 |
| Gescher, AJ | 1 |
| Sharma, RA | 1 |
| DeAntoni, E | 1 |
| Crawford, ED | 1 |
| Di Monaco, M | 1 |
| Brignardello, E | 1 |
| Leonardi, L | 1 |
| Gatto, V | 1 |
| Boccuzzi, G | 1 |
| Maucher, A | 1 |
| von Angerer, E | 1 |
| Vollmer, G | 1 |
| Michna, H | 1 |
| Schneider, MR | 1 |
| Blackledge, G | 1 |
| Kolvenbag, G | 2 |
| Nash, A | 1 |
| Kelly, WK | 2 |
| Slovin, S | 1 |
| Scher, HI | 2 |
| Liebertz, C | 1 |
| Mazumdar, M | 1 |
| Brett, C | 1 |
| Schwartz, L | 1 |
| Shapiro, L | 1 |
| Schwartz, M | 1 |
| Denis, L | 1 |
| Furuya, Y | 2 |
| Ozono, S | 1 |
| Hirao, Y | 1 |
| Montecchia, MF | 1 |
| Lamb, C | 1 |
| Molinolo, AA | 1 |
| Luthy, IA | 1 |
| Pazos, P | 1 |
| Charreau, E | 1 |
| Vanzulli, S | 1 |
| Lanari, C | 1 |
| Matsushima, H | 1 |
| Hosaka, Y | 1 |
| Kitamura, T | 1 |
| Kawabe, K | 1 |
| Taplin, ME | 1 |
| Bubley, GJ | 1 |
| Ko, YJ | 1 |
| Small, EJ | 1 |
| Upton, M | 1 |
| Rajeshkumar, B | 1 |
| Balk, SP | 1 |
| Richie, JP | 1 |
| Suzuki, K | 1 |
| Nakazato, H | 1 |
| Kurokawa, K | 1 |
| Yamanaka, H | 1 |
| Gandy, S | 1 |
| Almeida, OP | 1 |
| Fonte, J | 1 |
| Lim, D | 1 |
| Waterrus, A | 1 |
| Spry, N | 1 |
| Flicker, L | 1 |
| Martins, RN | 1 |
| Tanaka, S | 1 |
| Ueo, H | 1 |
| Mafune, K | 1 |
| Mori, M | 1 |
| Wands, JR | 1 |
| Sugimachi, K | 1 |
| Kwon, PS | 1 |
| Park, ES | 1 |
| Ellis, TM | 1 |
| Yang, D | 1 |
| Flanigan, RC | 1 |
| Waters, WB | 1 |
| Kast, WM | 1 |
| Nozaki, T | 1 |
| Nagakawa, O | 1 |
| Fuse, H | 1 |
| Huben, RP | 1 |
| Dawson, NA | 1 |
| Weiss, RB | 1 |
| Linehan, WM | 1 |
| Frank, JA | 1 |
| Jacob, JL | 1 |
| Gelmann, EP | 1 |
| Pavone-Macaluso, M | 1 |
| Serretta, V | 1 |
| Daricello, G | 1 |
| Pavone, C | 1 |
| Cacciatore, M | 1 |
| Romano, C | 1 |
| Cavallo, N | 1 |
| Waxman, J | 1 |
| Williams, G | 1 |
| Sandow, J | 1 |
| Hewitt, G | 1 |
| Abel, P | 1 |
| Farah, N | 1 |
| Fleming, J | 1 |
| Cox, J | 1 |
| O'Donoghue, EP | 1 |
| Sikora, K | 1 |
| Dupont, A | 2 |
| Bélanger, A | 2 |
| Lacourcière, Y | 2 |
| Monfette, JE | 1 |
| Monfette, G | 2 |
| Giguere, M | 1 |
| Borsanyi, JP | 1 |
| Lachance, R | 1 |
| Emond, J | 1 |
| Canellos, GP | 1 |
| Redding, TW | 1 |
| Schally, AV | 1 |
| Johansson, JE | 1 |
| Andersson, SO | 1 |
| Beckman, KW | 1 |
| Zador, G | 1 |
| Santen, RJ | 1 |
| Mowszowicz, I | 1 |
| Portois, MC | 1 |
| Mauvais-Jarvis, P | 1 |
| Namer, M | 1 |
| Boublil, JL | 1 |
| Kather, R | 1 |
| Cavaglione, G | 1 |
| Neumann, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE[NCT00767286] | Phase 3 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for flutamide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Cyproterone; Estrogens; Fluta | 2013 |
[Hormonal treatment in prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Benzamides; Co | 2013 |
[Keyrole of endocrinology in the victory against prostate cancer].
Topics: Adrenal Glands; Androgen Antagonists; Antineoplastic Agents, Hormonal; Dehydroepiandrosterone; Fluta | 2006 |
[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Mul | 1995 |
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Com | 1996 |
[Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Topics: Androgen Antagonists; Anilides; Chlormadinone Acetate; Flutamide; Humans; Male; Neoplasms, Hormone-D | 1998 |
[Total androgen blockade--concept, theory, method and clinical application].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flutamide; Gonadotropi | 1998 |
Anti-androgens and other hormonal therapies for prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Biomarkers, Tumor; Flutamide; Humans; Male; Neoplasms, Ho | 1999 |
[Basic and clinical characteristics of flutamide].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Neoplasms, Hormone-D | 2000 |
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E | 1990 |
16 trials available for flutamide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2009 |
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; H | 2009 |
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormon | 2012 |
Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2003 |
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antin | 2003 |
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; D | 2002 |
Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progres | 2004 |
Early effects of pharmacological androgen deprivation in human prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Flutamide; Humans; Leuprolide; Male; Neoplasms, Hormone- | 2007 |
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Com | 1996 |
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1998 |
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.
Topics: Androgen Antagonists; Antigen-Presenting Cells; Antineoplastic Agents, Hormonal; Breast Neoplasms; C | 2001 |
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbest | 1992 |
A pilot trial of chemohormonal therapy for metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug E | 1992 |
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E | 1990 |
The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyp | 1988 |
Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Anilides; Bone Neoplasms; Estramustine; Flutamide; Follow-Up Studies; Humans; | 1988 |
36 other studies available for flutamide and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Boranes; Cell | 2010 |
Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Blood-Brain Barrier; Drug Design; Drug Screeni | 2011 |
Choice of first-line treatment for metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Estrogens; Flutamide; Goserel | 2013 |
Gene microarray assessment of multiple genes and signal pathways involved in androgen-dependent prostate cancer becoming androgen independent.
Topics: Androgen Antagonists; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Flutamide; Ge | 2014 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug E | 2011 |
Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
Topics: Androgen Antagonists; Androgens; Blotting, Western; Cell Line, Tumor; Dihydrotestosterone; Estrogens | 2010 |
[Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Castration; Flutamid | 2011 |
Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide.
Topics: Androgen Antagonists; Androgens; Blotting, Western; Dihydrotestosterone; Estrogens; Estrone; Flutami | 2012 |
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans | 2002 |
[Expression of androgen receptor protein in hormone refractory prostate cancer].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Follow-Up | 2003 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides | 2002 |
Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.
Topics: Androgen Antagonists; Anilides; Autocrine Communication; BCG Vaccine; Carcinoma, Transitional Cell; | 2003 |
Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Follow-Up | 2004 |
Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Cell Line, Tumor; Enzyme Induction; Flutamide; Gene Expression Regu | 2004 |
[Effect of dihydrotestosterone on the transcriptions and expressions of Smad3 and Smad4 in LNCaP cell line].
Topics: Androgens; Cell Line, Tumor; Dihydrotestosterone; Flutamide; Humans; Male; Neoplasms, Hormone-Depend | 2006 |
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Topics: Allylestrenol; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cyproterone | 2007 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo.
Topics: Androgens; Animals; Cell Line, Tumor; Dihydrotestosterone; DNA Adducts; DNA Damage; Flutamide; Human | 2008 |
Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Dihydrotestosterone | 1995 |
Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1993 |
Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma.
Topics: Androgen Antagonists; Animals; Cyproterone Acetate; Flutamide; Male; Neoplasm Proteins; Neoplasms, H | 1996 |
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Neoplasms, Hormone-D | 1997 |
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; | 1997 |
Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas.
Topics: Adenocarcinoma; Androgens; Animals; Binding Sites; Estradiol; Female; Flutamide; Glucocorticoids; Go | 1999 |
Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Antigens, Neoplasm; Antineoplastic Agents, Ho | 1999 |
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Bone Marrow; Bone Marrow Ne | 1999 |
Chemical andropause and amyloid-beta peptide.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Androgen Antagoni | 2001 |
A novel isoform of human fibroblast growth factor 8 is induced by androgens and associated with progression of esophageal carcinoma.
Topics: Androgen Antagonists; Androgens; Biomarkers; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fibrobl | 2001 |
Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chlormadinone Ac | 2002 |
[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Flutam | 1986 |
Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Topics: Adenocarcinoma; Androgens; Anilides; Combined Modality Therapy; Evaluation Studies as Topic; Flutami | 1987 |
Hormonal agents and treatment of cancer.
Topics: Androgens; Breast Neoplasms; Diethylstilbestrol; Dihydrotestosterone; Estrogens; Female; Flutamide; | 1986 |
Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Topics: Anilides; Animals; Body Weight; Cell Line; Drug Therapy, Combination; Flutamide; Gonadotropin-Releas | 1985 |
Androgen dependence of the Dunning R3327G cell line in monolayer culture.
Topics: Androgen Antagonists; Androgens; Animals; Cell Division; Cell Line; Dihydrotestosterone; Flutamide; | 1987 |
[Cancer of the prostate: new hormone therapies].
Topics: Androgen Antagonists; Cyproterone; Flutamide; Humans; Ketoconazole; Male; Medroxyprogesterone; Meges | 1986 |
Principles of endocrine manipulation in the treatment of prostatic cancer.
Topics: Androgen Antagonists; Animals; Castration; Cyproterone; Estrogens; Flutamide; Gonadotropin-Releasing | 1985 |